
Sign up to save your podcasts
Or
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
4
77 ratings
Suboptimal dosing of renin-angiotensin-aldosterone system inhibitors (RAASi) therapy is associated with doubling of mortality. Experts discuss new options for intensification of RAASi in heart failure with reduced ejection fraction (HFrEF). Credit available for this activity expires: 9/29/2024 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/996906?ecd=bdc_podcast_libsyn_mscpedu
137 Listeners
319 Listeners
500 Listeners
101 Listeners
883 Listeners
13 Listeners
17 Listeners
289 Listeners
3,339 Listeners
1,149 Listeners
190 Listeners
88 Listeners
514 Listeners
369 Listeners
61 Listeners
26 Listeners
432 Listeners
372 Listeners